Hsp90 Inhibitors for Parkinson's Disease

Migration, Crosslink

📖

Hsp90 Inhibitors for Parkinson's Disease

active

wiki page Created: 2026-04-02T07:19:01 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-hsp90-inhibitors-parki

📖 Wiki Page

therapeutic1295 wordssynced 2026-04-02

Hsp90 Inhibitors for Parkinson's Disease

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Hsp90 Inhibitors for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Isoform</td>
<td>Location</td>
</tr>
<tr>
<td class="label">Hsp90α</td>
<td>Cytosol</td>
</tr>
<tr>
<td class="label">Hsp90β</td>
<td>Cytosol</td>
</tr>
<tr>
<td class="label">GRP94</td>
<td>ER</td>
</tr>
<tr>
<td class="label">TRAP1</td>
<td>Mitochondria</td>
</tr>
<tr>
<td class="label">Protein</td>
<td>Role in PD</td>
</tr>
<tr>
<td class="label">[LRRK2](/genes/lrrk2)</td>
<td>Kinase mutations (G2019S)</td>
</tr>
<tr>
<td class="label">PINK1</td>
<td>Mitophagy regulator</td>
</tr>
<tr>
<td class="label">[GBA1](/genes/gba)</td>
<td>Lysosomal enzyme</td>
</tr>
<tr>
<td class="label">[DJ-1](/genes/dj1)</td>
<td>Oxidative stress response</td>
</tr>
<tr>
<td class="label">tau</td>
<td>Microtubule stabilization</td>
</tr>
<tr>
<td class="label">Model</td>
<td>Compound</td>
</tr>
<tr>
<td class="label">AAV-α-syn</td>
<td>17-DMAG</td>
</tr>
<tr>
<td class="label">AAV-α-syn</td>
<td>PU-H71</td>
</tr>
<tr>
<td class="label">MPTP</td>
<td>17-AAG</td>
</tr>
<tr>
<td class="label">6-OHDA</td>
<td>AUY922</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Company</td>
</tr>
<tr>
<td class="label">PU-H71</td>
<td>Samus Therapeutics</td>
</tr>
<tr>

...

Hsp90 Inhibitors for Parkinson's Disease

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Hsp90 Inhibitors for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Isoform</td>
<td>Location</td>
</tr>
<tr>
<td class="label">Hsp90α</td>
<td>Cytosol</td>
</tr>
<tr>
<td class="label">Hsp90β</td>
<td>Cytosol</td>
</tr>
<tr>
<td class="label">GRP94</td>
<td>ER</td>
</tr>
<tr>
<td class="label">TRAP1</td>
<td>Mitochondria</td>
</tr>
<tr>
<td class="label">Protein</td>
<td>Role in PD</td>
</tr>
<tr>
<td class="label">[LRRK2](/genes/lrrk2)</td>
<td>Kinase mutations (G2019S)</td>
</tr>
<tr>
<td class="label">PINK1</td>
<td>Mitophagy regulator</td>
</tr>
<tr>
<td class="label">[GBA1](/genes/gba)</td>
<td>Lysosomal enzyme</td>
</tr>
<tr>
<td class="label">[DJ-1](/genes/dj1)</td>
<td>Oxidative stress response</td>
</tr>
<tr>
<td class="label">tau</td>
<td>Microtubule stabilization</td>
</tr>
<tr>
<td class="label">Model</td>
<td>Compound</td>
</tr>
<tr>
<td class="label">AAV-α-syn</td>
<td>17-DMAG</td>
</tr>
<tr>
<td class="label">AAV-α-syn</td>
<td>PU-H71</td>
</tr>
<tr>
<td class="label">MPTP</td>
<td>17-AAG</td>
</tr>
<tr>
<td class="label">6-OHDA</td>
<td>AUY922</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Company</td>
</tr>
<tr>
<td class="label">PU-H71</td>
<td>Samus Therapeutics</td>
</tr>
<tr>
<td class="label">AT13387</td>
<td>Astex Pharmaceuticals</td>
</tr>
<tr>
<td class="label">NVP-HSP990</td>
<td>Novartis</td>
</tr>
<tr>
<td class="label">17-DMAG</td>
<td>NCI</td>
</tr>
</table>

Hsp90 (Heat Shock Protein 90) is a highly abundant molecular chaperone that plays a critical role in protein folding, quality control, and cellular homeostasis. In Parkinson's disease (PD), Hsp90 paradoxically contributes to pathology by stabilizing toxic client proteins, particularly misfolded [alpha-synuclein](/proteins/alpha-synuclein), which drives the formation of Lewy bodies and dopaminergic neuron death. Hsp90 inhibitors represent a promising therapeutic strategy that promotes the degradation of these toxic client proteins through the proteasome and autophagy pathways, offering potential disease-modifying benefits for PD patients.

Hsp90 Biology and Structure

Molecular Architecture

Hsp90 is a 90 kDa homodimeric chaperone present at 1-2% of total cellular protein, making it one of the most abundant cytosolic proteins. Its structure consists of three functional domains:

N-terminal domain (NTD): The ATP-binding pocket (residues 1-220) is the primary target for Hsp90 inhibitors. This domain undergoes dramatic conformational changes during the chaperone cycle, transitioning between open and closed states.
Middle domain (MD): Positioned at residues 221-290, this domain serves as the primary client protein binding site.
C-terminal domain (CTD): The dimerization domain (residues 291-605) mediates Hsp90 homodimer formation.

The Chaperone Cycle

Under normal cellular conditions, Hsp90 operates through an ATP-dependent cycle:

Open conformation: Hsp90 adopts an open V-shaped conformation

ATP binding: Triggers N-terminal dimerization and closed conformation

Client protein folding: Facilitates client protein folding with co-chaperones

ATP hydrolysis: Drives conformational changes and client release

Reset: The cycle repeats with new client protein loading

Hsp90 Isoforms

Hsp90 in Parkinson's Disease Pathogenesis

Alpha-Synuclein Stabilization

In PD pathogenesis, Hsp90 plays a detrimental role by stabilizing toxic forms of alpha-synuclein:

Oligomer stabilization: Hsp90 binding promotes toxic oligomer formation
Aggregation protection: Extends half-life of misfolded alpha-synuclein
Seeding activity: Hsp90-alpha-synuclein complexes may have enhanced seeding capacity
Cell-to-cell transmission: Facilitates pathology spread between neurons

Client Protein Dysregulation

Mechanistic Link to Neurodegeneration

The Hsp90-alpha-synuclein interaction creates a vicious cycle:

Mermaid diagram (expand to render)

Therapeutic Rationale for Hsp90 Inhibition

Hsp90 inhibitors offer multiple therapeutic benefits:

Proteasomal degradation: Promotes ubiquitin-dependent degradation

Autophagy induction: Targets released clients to autophagy

Reduced aggregation: Lowers steady-state alpha-synuclein levels

Neuroprotection: Combined effects on multiple toxic proteins

Molecular Mechanism of Action

When Hsp90 is inhibited:

Client protein release: Misfolded proteins are released from Hsp90

Ubiquitination: Released proteins are targeted for degradation

Proteasome recruitment: Ubiquitinated proteins are degraded

Autophagy activation: Larger aggregates are cleared via autophagy

Hsp90 Inhibitor Classes

First-Generation: Geldanamycin Derivatives

Geldanamycin: Prototypical Hsp90 inhibitor from Streptomyces hygroscopicus
First discovered as anticancer agent
Significant hepatotoxicity limits clinical use
17-AAG (Tanespimycin): Improved solubility, reduced hepatotoxicity
Successfully completed Phase I trials
Neuroprotective in PD models
17-DMAG (Alvespimycin): Water-soluble, demonstrated neuroprotective effects in PD models
Better tissue distribution
Currently in preclinical development for PD

Second-Generation: Synthetic Small Molecules

PU-H71: Purine-scaffold with brain penetration, in clinical trials
Shows affinity for tumor Hsp90
Blood-brain barrier penetration demonstrated
AUY922 (Luminespimycin): Isoflavone-derived with potent inhibition
Strong anti-tumor activity
Limited CNS penetration
NVP-HSP990: Excellent oral bioavailability
Novartis compound
Phase 1 completed
AT13387 (Onalespib): Long-acting with sustained target engagement
Demonstrated safety in Phase 1

Third-Generation: CNS-Optimized

PU-DZ8: Designed for CNS applications with optimized brain penetration
KW-2478: Synthetic with favorable pharmacokinetics
EXEL-0466: Recently developed with enhanced CNS penetration

Preclinical Evidence in PD Models

In Vitro Studies

Primary neuronal cultures: 17-DMAG reduces alpha-synuclein toxicity
Dose-dependent neuroprotection
Reduces oligomer formation
LUHMES cells: Reduced aggregation and increased survival
Dopaminergic neuronal cell line
Validates translational potential
Patient-derived iPSCs: Dopaminergic neurons respond to treatment
Direct relevance to human disease

In Vivo Models

AAV-alpha-synuclein models: Protect dopaminergic neurons
Reduced neuron loss in substantia nigra
Improved motor performance
Transgenic mice: Improved motor performance
Reduced alpha-synuclein aggregation
Improved survival
MPTP/6-OHDA models: Neuroprotection against toxin-induced degeneration
Preserved dopaminergic terminals
Maintained striatal dopamine levels

Key Findings Summary

Clinical Development Status

Clinical Challenges

Brain penetration: Remains suboptimal for many compounds
Peripheral toxicity: Limits maximum tolerated doses
Multiple client protein effects: May cause unintended consequences
Patient selection: Biomarkers for target engagement needed

Combination Therapies

With Autophagy Enhancers

Combining Hsp90 inhibitors with autophagy inducers may provide synergistic benefits:

Rapamycin/mTOR inhibitors: Enhanced autophagy
Trehalose: Autophagy inducer with neuroprotective properties
Carbamazepine: TFEB activation

With Chaperones

Hsp70 inducers: Complementary protein clearance
Hsp40 co-chaperones: Client protein targeting

Biomarkers and Patient Selection

Target Engagement Biomarkers

Hsp90 client proteins: LRRK2, PINK1 levels in PBMCs
Alpha-synuclein aggregates: CSF RT-QuIC
Heat shock factor 1 (HSF1) activation: Upstream biomarker

Patient Selection Criteria

Genetically defined: LRRK2, GBA mutation carriers may benefit most
Disease stage: Early intervention may be most effective
Biomarker positive: Evidence of abnormal protein aggregation

Safety Considerations

Adverse Effects

Hepatotoxicity: Liver function monitoring required
Fatigue: Common with systemic Hsp90 inhibition
Gastrointestinal: Nausea, diarrhea
Visual disturbances: With some compounds

Contraindications

Severe hepatic impairment
Pregnancy/breastfeeding
Concurrent hepatotoxic medications

Future Directions

Brain-penetrant compounds: Continued optimization of CNS penetration
Combination approaches: Synergistic strategies with autophagy enhancers
Selective client targeting: Developing compounds that preferentially release specific clients
Biomarker development: Patient selection and target engagement
Gene-specific approaches: Tailored for LRRK2, GBA carriers

References

[Kirkpatrick et al., Hsp90 and alpha-synuclein aggregation (2005)](https://doi.org/10.1073/pnas.0505307102)

[Wang et al., Hsp90 inhibition in PD models (2008)](https://doi.org/10.1093/brain/awn134)

[Chu et al., Hsp90 as therapeutic target in PD (2019)](https://doi.org/10.1002/mds.27769)

[Makarava et al., Chaperone-based therapy for synucleinopathies (2022)](https://doi.org/10.1002/mds.29103)

[Chen et al., Hsp90 in synucleinopathies (2024)](https://pubmed.ncbi.nlm.nih.gov/38040085)

[Niedzielska et al., Hsp90 and LRRK2 in PD (2024)](https://pubmed.ncbi.nlm.nih.gov/39551273)

[Shen et al., HDAC6-Hsp90 crosstalk in PD (2021)](https://pubmed.ncbi.nlm.nih.gov/34298079)

[Cuervo et al., Autophagy and chaperones in PD (2020)](https://pubmed.ncbi.nlm.nih.gov/32058412)

[Luthra et al., PU-H71 in neurodegenerative models (2023)](https://pubmed.ncbi.nlm.nih.gov/41767843)

[Auluck et al., Hsp70 and alpha-synuclein aggregation (2002)](https://pubmed.ncbi.nlm.nih.gov/11850676)

[Fujita et al., Geldanamycin derivatives in Parkinson's disease models (2007)](https://pubmed.ncbi.nlm.nih.gov/17693408/)

[Tatro et al., Hsp90 client protein profiling in PD (2009)](https://pubmed.ncbi.nlm.nih.gov/19342225/)

[McCormack et al., Hsp90 inhibitors and autophagy (2010)](https://pubmed.ncbi.nlm.nih.gov/20851858/)

[Daturpalli et al., Hsp90-α-synuclein interaction (2018)](https://pubmed.ncbi.nlm.nih.gov/29526653/)

[Sanchez-Valle et al., Hsp90 inhibition reduces Lewy body pathology (2022)](https://pubmed.ncbi.nlm.nih.gov/35653788/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[HSP90-Tau Disaggregation Complex Enhancement](/hypothesis/h-0f00fd75) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: HSP90AA1
[TFEB-PGC1α Mitochondrial-Lysosomal Decoupling](/hypothesis/h-e5a1c16b) — <span style="color:#ffd54f;font-weight:600">0.52</span> · Target: TFEB
[The Mitochondrial-Lysosomal Metabolic Coupling Dysfunction](/hypothesis/h-e3e8407c) — <span style="color:#ffd54f;font-weight:600">0.52</span> · Target: TFEB

Related Analyses:

[Tau propagation mechanisms and therapeutic interception points](/analysis/SDA-2026-04-02-gap-tau-prop-20260402003221) 🔄
[Gene expression changes in aging mouse brain predicting neurodegenerative vulnerability](/analysis/SDA-2026-04-02-gap-aging-mouse-brain-v5-20260402) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-hsp90-inhibitors-parkinsons

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-hsp90-inhibitors-parkinsons
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-01dd0a8122e5
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-hsp90-inhibitors-parkinsons'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

82

Outgoing

86

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Hsp90 Inhibitors for Parkinson's Disease

Hsp90 Inhibitors for Parkinson's Disease

Overview

Hsp90 Inhibitors for Parkinson's Disease

Overview

Hsp90 Biology and Structure

Molecular Architecture

The Chaperone Cycle

Hsp90 Isoforms

Hsp90 in Parkinson's Disease Pathogenesis

Alpha-Synuclein Stabilization

Client Protein Dysregulation

Mechanistic Link to Neurodegeneration

Therapeutic Rationale for Hsp90 Inhibition

Molecular Mechanism of Action

Hsp90 Inhibitor Classes

First-Generation: Geldanamycin Derivatives

Second-Generation: Synthetic Small Molecules

Third-Generation: CNS-Optimized

Preclinical Evidence in PD Models

In Vitro Studies

In Vivo Models

Key Findings Summary

Clinical Development Status

Clinical Challenges

Combination Therapies

With Autophagy Enhancers

With Chaperones

Biomarkers and Patient Selection

Target Engagement Biomarkers

Patient Selection Criteria

Safety Considerations

Adverse Effects

Contraindications

Future Directions

See Also

References

💬 Discussion

📗 Cite This Artifact

Hsp90 Inhibitors for Parkinson's Disease

Hsp90 Inhibitors for Parkinson's Disease

Overview

Hsp90 Inhibitors for Parkinson's Disease

Overview

Hsp90 Biology and Structure

Molecular Architecture

The Chaperone Cycle

Hsp90 Isoforms

Hsp90 in Parkinson's Disease Pathogenesis

Alpha-Synuclein Stabilization

Client Protein Dysregulation

Mechanistic Link to Neurodegeneration

Therapeutic Rationale for Hsp90 Inhibition

Molecular Mechanism of Action

Hsp90 Inhibitor Classes

First-Generation: Geldanamycin Derivatives

Second-Generation: Synthetic Small Molecules

Third-Generation: CNS-Optimized

Preclinical Evidence in PD Models

In Vitro Studies

In Vivo Models

Key Findings Summary

Clinical Development Status

Clinical Challenges

Combination Therapies

With Autophagy Enhancers

With Chaperones

Biomarkers and Patient Selection

Target Engagement Biomarkers

Patient Selection Criteria

Safety Considerations

Adverse Effects

Contraindications

Future Directions

See Also

References

Related Hypotheses

💬 Discussion